NEWS

1 Treatment for ADHD reduces criminal behaviour
Doctors must put needs of child before relationship
with parents, judge rules

2 GP is held responsible for brain damage of child who
was discharged from hospital after head injury
Belief not science is behind flu jab promotion

3 Mammography again linked to cancer overdiagnosis

4 Fasting makes little difference to results of routine
lipid level tests
Investigations begin into death of woman who was
refused an abortion

5 Missing notes mean case against doctor arrested in
UAE is deferred
UK could get first meningitis B vaccine next year

6 Smokers respond more to pictures than words
Recession leads to first fall in health spending in
Europe since 1975, says OECD report
Family of patient who died during a trial receives a
six figure settlement

RESEARCH

RESEARCH HIGHLIGHTS

11 The pick of BMJ research papers this week

12 All you need to read in the other general journals

14 General health checks in adults for reducing
morbidity and mortality from disease: Cochrane
systematic review and meta-analysis
Lasse T Krogsbøll et al

15 Effect of intensive structured care on individual
blood pressure targets in primary care: multicentre
randomised controlled trial
On behalf of the VIPER-BP study investigators

16 Muscular strength in male adolescents and premature
death: cohort study of one million participants
Francisco B Ortega et al

17 Sharing of clinical trial data among trialists: a cross
sectional survey
Vinay Rathi et al

18 Efficacy and safety of novel oral anticoagulants for
treatment of acute venous thromboembolism: direct
and adjusted indirect meta-analysis of randomised
controlled trials
Benjamin D Fox et al

ANALYSIS

23 How to achieve international action on falsified and
substandard medicines
Substandard and falsified medicines kill patients,
yet progress on the twin challenges of safeguarding
the quality of genuine medicine and criminalising
falsified ones has been held back by controversy over
intellectual property rights and confusion over terms.
Amir Attaran and colleagues propose a global treaty
to overcome the problems

FEATURES

28 Faking it
Globalisation has helped increase the risks of
counterfeit drugs endangering human life. Andrew
Jack looks at the scale of the problem and the latest
attempts to crack down on crime
**COMMENT**

**LETTERS**

30 Breast screening review; Safety of antithrombosis stockings; Prison environment and health
31 Awareness about antibiotics; Diagnosis of tuberculosis; Salivary gland swellings
32 Myalgia while taking statins; Imprisonment of Cyril Karabus; Bad medicine: medical nutrition
33 Future of WHO; Whistleblowing barriers in the NHS; Forty years of murder

**OBSERVATIONS**

LIFE AND DEATH
34 Falling through the gaps in care Iona Heath

ETHICS MAN
35 How good a doctor do you need to be? Daniel K Sokol

**VIEWS AND REVIEWS**

PERSONAL VIEW
36 Junior doctors take heart Anthony Cohn

**BETWEEN THE LINES**

37 The tale of a mad hatter Theodore Dalrymple

**MEDICAL CLASSICS**

37 The Ha Ha A novel by Jennifer Dawson
Kate Robertson

**OBITUARIES**

38 Edward Donnall Thomas
Nobel laureate, known as the father of bone marrow transplantation

39 Peter William Hayward; Colin Kaplan; Cyril Jacob Kaplan; Alan Colin Markland; Elwyn Roberts; Jose A Socrates; Thomas Glyn Thomas

**LAST WORDS**

51 The peeved middle Des Spence
A short history of pharmaceutical marketing Robin Ferner

**EDUCATION**

**CLINICAL REVIEW**

40 Resistant hypertension Aung Myat et al

**PRACTICE**

CHANGE PAGE

46 Administer tranexamic acid early to injured patients at risk of substantial bleeding
Russell L Gruen and Michael C Reade

**A PATIENT’S JOURNEY**

48 Neuromuscular degeneration Caroline Fisher and Nicole Freris

**ENDGAMES**

50 Quiz page for doctors in training

**MINERVA**

52 Quails’ eggs, and other stories

---

**Too much information and not enough time?**

BMJ Masterclasses

masterclasses.bmj.com
Doctors who have launched a new political party that promises to make the NHS one of the key issues at the next election gathered in London last week. They aim to oppose the government’s changes to healthcare and to protect the NHS from the threat of austerity measures. The party hopes to put forward up to 50 parliamentary candidates in 2015 in carefully selected areas and in local elections.

**PICTURE OF THE WEEK**

This week’s poll asks: “In view of increasing antimicrobial resistance worldwide, have you changed your prescribing practice for antibiotics?”

73% voted yes (total 467 votes cast)

**RESPONSE OF THE WEEK**

This article makes explicit the approach that many general practitioners feel they already aspire to, and being aware of our personal biases and cognitive processes during the consultation can only help us to become better doctors. Unfortunately, in the UK this approach is coming under increasing threat.

Despite the government’s mantra ‘no decision about me without me,’ the reality is that with the increasing demands from performance management, GPs are under pressure to disregard patient preferences and to manage them according to strict and simplistic protocols. The proposed new GP contract threatens to intensify this. In one of the many internal tensions within the current NHS, the claim to honour the wishes of the patient is at odds with the desire to micromanage how we treat them. As the QOF juggernaut hurts blindly onward, shared decision making will be one of the casualties.

Jonathan D Sleath, general practitioner, Hereford, UK, in response to “Stop the silent misdiagnosis: patients’ preferences matter” (BMJ 2012;345:e6572)

**MOST COMMENTED ON**

Association between fish consumption, long chain omega 3 fatty acids, and risk of cerebrovascular disease

**MOST READ**

Clinical trial data for all drugs in current use

Minerva

Psychotic depression

Plantar fasciitis

Promoting cosmetic surgery

Breast screening is beneficial, panel concludes, but women need to know about harms

A licence to bill
In an article this week a self defined “diverse group of authors from the health professions, health charities, legal and medical academia, and former or current government officials in health” present us with a troubling paradox: the world currently has tighter laws to tackle fake tobacco products than it does to tackle fake drugs (p 23). At the moment, as they explain, there are laws that promote an open global medicines trade but no binding international health law on drug safety. The result is that fake and substandard drugs continue to harm and kill people around the world, affecting both proprietary and generic drugs, and haunting rich countries as well as poor. As Andrew Jack explains (p 28), the rapid growth of unregulated internet sales of drugs has raised the stakes even further. In the accompanying podcast, Amir Attiran emphasises the absurd situation by which trading fake medicines is currently legal under international law, and Sania Nishtar highlights worryingly weak pharmacovigilance systems in Pakistan (www.bmj.com/multimedia).

Why the lack of progress on this globally damaging health problem? There’s no simple answer to what is clearly a complex problem, but the authors suggest that the main barriers have been the lack of an internationally agreed terminology and a focus in law on commercial interests rather than public health.

Progress has also been hampered by a lack of good data on the scale of the problem. WHO estimates that over 10% of drugs in developing countries may be “counterfeit,” but getting a better idea of the impact is proving difficult. The drug industry keeps records of “medicine crimes,” but these are held in secret so are not available to researchers or governments wanting to raise awareness and improve patient safety. But recent incidents are focusing minds. Contaminated methylprednisolone has killed 28 people from meningitis in the United States this year (BMJ 2012;345:e7095) and more than 125 people were killed in Pakistan by generic isosorbide-5-mononitrate tablets adulterated with a toxic dose of antimalarial (BMJ 2012;344:e951). These incidents are the visible tip of a vast iceberg of failed treatment, adverse reaction, and death.

With less than a third of WHO member states having well developed drug regulation, reliance on national governments to resolve things is unlikely to work. In a linked commentary, Thomas Dorlo and colleagues call for more resources to support national regulators (p 27).

The BMJ “diverse group of authors” has come together to call for global action. They propose a treaty modelled on the successful Framework Convention on Tobacco Control and, to help get us there, a simpler terminology. In place of WHO’s current all encompassing working definition “SFFC”—which stands for spurious, falsely labelled, falsified, counterfeit medical products, and which in some versions has an additional “S” for substandard—they propose a clearer focus on falsified and substandard drugs.

Both categories cause harm but they require different remedies. “Falsified medicines are deliberate, intentional frauds and should be prohibited using criminal measures. In contrast, substandard medicines are unintentional or negligent errors that require regulatory measures to correct.” The US methylprednisolone incident looks likely to have been caused by poor standards rather than criminal intent. In Pakistan, if allegations are confirmed that the company knew of the error and sold the drug anyway, the incident may be reclassified as falsified.

This week, WHO member states met in Buenos Aires to try to take things forward. They could do worse than to follow these authors’ advice.

Fiona Godlee, editor, BMJ fgodlee@bmj.com

Cite this as: BMJ 2012;345:e7917